Weight Loss Pill vs Injection: What's the Real Difference?

Are a daily tablet and a weekly injection actually the same medicine?

Almost, but not quite interchangeable. The once-weekly injection for weight management is Wegovy, which contains semaglutide at up to 2.4mg per dose (with a newer 7.2mg pen now MHRA-approved). The tablet (Wegovy in oral form) was approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management; the UK was the first country in Europe to authorise it. Both are made by Novo Nordisk and act on the same GLP-1 receptor, slowing gastric emptying and reducing appetite signals in the brain.

The practical gap is bioavailability. When semaglutide is swallowed, only a fraction reaches the bloodstream, so the oral version is co-formulated with an absorption enhancer called SNAC and taken at a much higher dose (up to 25mg daily) to achieve a comparable therapeutic effect. The injection delivers semaglutide directly into subcutaneous tissue, bypassing first-pass metabolism entirely, which is why weekly doses remain in the low milligrams.

There is a third licensed option worth knowing about: tirzepatide (Mounjaro), a once-weekly injection that activates two gut-hormone receptors rather than one. It is not available as a tablet. The comparison below includes all three so you can see the full picture at a glance.

One note on Ozempic and Rybelsus: both contain semaglutide and both are oral or injectable medicines you may have heard mentioned. Neither is licensed for weight management in the UK, they are authorised for type 2 diabetes. A prescriber cannot lawfully issue them for weight loss on that basis. The medicines above are the licensed routes. More detail on what pill options actually exist is worth reading if this distinction matters to your decision.

Does the pill work as well as the injection?

In trial terms, the oral tablet produced meaningful weight loss, around 13.6% on average across all participants in the OASIS 4 phase 3 study, rising to about 17% among those who stayed fully adherent to the regimen. That 17% figure deserves context: it reflects the best-case adherent group, not the overall average, so the 13.6% number is the more honest headline. The weekly semaglutide injection showed roughly 15% average loss in STEP 1. The injectable tirzepatide sits higher still, with the SURMOUNT-5 head-to-head trial (published in the New England Journal of Medicine, 2025) reporting greater average reduction with tirzepatide than with semaglutide 2.4mg.

Numbers from separate trials are never perfectly comparable, population, duration, lifestyle support and adherence all shift the result. A closer look at how pill and injection outcomes compare walks through what the evidence actually supports. The honest summary is that the pill can work well, particularly for people who find the weekly injection a barrier, but the average trial results currently favour the injections, especially tirzepatide.

Side effects across all three share a GI-led profile: nausea, loose stools, constipation and indigestion are the most commonly reported, typically most noticeable when starting or after a dose step, and often easing within a week or two. The oral tablet saw somewhat higher rates of GI effects in its trial (74% of participants reported them versus 42% on placebo) likely reflecting the higher absolute dose reaching the gut. The NHS page on semaglutide lists the full side-effect profile with guidance on when to contact a doctor.

When might someone choose the tablet over the injection?

Needle aversion is the most obvious reason, and it is entirely valid. For some people, a daily tablet slots more naturally into a morning routine than a weekly injection, before the kettle goes on, nothing else taken for at least half an hour. The no-refrigeration requirement also matters practically: travel, staying away from home, jobs with irregular access to a fridge. Those are real-world factors a prescriber weighs alongside the clinical picture.

On the other side, the daily dosing schedule of the tablet demands more consistent habit-formation than a once-weekly injection. Missing occasional doses of the tablet has a more direct impact on therapeutic levels than a single delayed injection week. The 30-minute empty-stomach window before food or drink (including coffee) is also a genuine daily commitment some people find easier said than maintained.

People already established on the 2.4mg weekly injection may move to the 25mg tablet under clinical supervision, subject to prescriber assessment. That switching pathway is new, and guidance is evolving, your prescriber is the right person to judge whether it makes sense for your situation. Further reading on transitioning between forms covers what that process typically involves.

Cost context is worth a sentence. Private treatment pricing varies by dose and provider; any legitimate price includes a prescription, clinical assessment and typically delivery. What headline prices sometimes exclude (aftercare, dose-review support, prescription fees) is worth checking before comparing numbers. At nume, one price covers all of it: consultation, prescription, treatment and free next-working-day delivery, with clinical re-review before every repeat. We are not the cheapest option; that is a deliberate choice. More on what private injection costs typically include sets out what to look for.

Which option is right for you?

That is exactly the question a prescriber should answer with you, not a comparison page. Eligibility for any of these medicines depends on your BMI, your health history, any medicines you already take and factors a chart cannot capture. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance; the prescriber accounts for that too.

There are also interaction points worth knowing about. For tirzepatide specifically, the NHS advises adding a non-oral contraception method during the first four weeks of treatment and for four weeks after each dose increase, because absorption of the oral contraceptive pill may be affected. No equivalent interaction has been identified for injectable semaglutide. NHS England's guidance on weight management injections covers this and related safety points in detail.

At nume, every consultation is reviewed the same day by a GPhC-registered Independent Prescriber. If you place an order before 12pm on a working day (helpful to know if payday lines up with a Monday) and are approved as clinically suitable, your treatment goes out the same afternoon. Which of these medicines, if any, suits your circumstances is the conversation our prescribers are here to have. Start your free consultation when you're ready, or read more about our treatment options first.